ovalbumin

Overview

Ovalbumin (OVA) is the major storage protein of egg white, constituting approximately 54% of its total protein content. It is a monomeric phosphoglycoprotein with a molecular weight of approximately 45 kDa, belonging to the serpin superfamily despite lacking protease inhibitory activity. Structurally, ovalbumin contains a reactive center loop and undergoes conformational transitions between its native (N) and heat-stable (S) forms. Beyond its nutritional role in avian eggs, ovalbumin is widely recognized in biomedical research as a soluble, well-characterized model antigen. Its defined molecular structure, predictable immunogenic epitopes — including the well-studied MHC class I-restricted peptide SIINFEKL — and commercial availability have made it indispensable for dissecting antigen presentation pathways, T cell activation, and immune responses in controlled experimental settings. Ovalbumin also exhibits amphiphilic surface-active properties, giving it utility as a biopolymer emulsifier and carrier material in food science and pharmaceutical formulation.

As a model antigen, ovalbumin occupies a unique position at the intersection of immunology, vaccinology, allergy research, and drug delivery. It can elicit both humoral and cell-mediated immune responses, drive CD8+ cytotoxic T cell priming through cross-presentation, and sensitize animals to produce allergen-specific IgE, making it suitable for modeling conditions ranging from cancer immunotherapy to allergic asthma and hypersensitivity disorders. Its dual utility — as both an immunological tool and a functional biopolymer — has sustained its relevance across a broad spectrum of contemporary biomedical investigations.

Focus of Latest Publications

Recent literature demonstrates ovalbumin's continued centrality as both a functional biomaterial and an immunological probe across highly diverse research areas.

cancer immunotherapy and mRNA Vaccine Delivery

A prominent 2026 study published in Bioactive Materials (PMID: 41737632) exploited ovalbumin-encoding messenger RNA to evaluate novel lipid nanoparticle (LNP) delivery platforms. Specifically, H-type ionizable lipid-based LNPs were engineered to target splenic dendritic cells following intravenous administration. OVA mRNA-loaded nanoparticles effectively activated antigen-specific CD8+ T cells in B16-OVA tumor-bearing mouse models, and parallel experiments using tyrosinase-related protein 2 (Trp2) mRNA demonstrated significant antitumor efficacy in B16F10 models. This work highlights ovalbumin's role as a tractable surrogate for tumor-associated antigens in evaluating cancer immunotherapy platforms. In a complementary study (International Journal of Biological Macromolecules, PMID: 42119872), OVA served as the model antigen for assessing the adjuvant capacity of nanosized curdlan sulfate/quaternary ammonium chitosan/CpG ODN polyelectrolyte complexes, with results informing the rational design of adjuvanted tumor vaccines. OVA's well-defined antigenicity makes it ideal for benchmarking immune activation potency, particularly in contexts involving cytotoxic T cell responses and nuclear factor kappa B-mediated inflammatory signaling.

A study targeting glioblastoma (GBM) immunotherapy (Biomaterials, PMID: 41370882) demonstrated that M2-like tumor-associated macrophages in GBM could be reprogrammed to cross-present OVA antigen carried by nanoparticles (NPs-RuIn-M), effectively promoting the activation and proliferation of CD8+ T cells and inhibiting GBM tumor growth. This study underscores ovalbumin's utility in evaluating antigen cross-presentation mechanisms — a process critical to cancer immunotherapy — and in assessing strategies to overcome the blood–brain barrier in the context of brain tumor treatment.

Mucosal Vaccination

A landmark 2026 study in Science (PMID: 41712698) employed ovalbumin as a model antigen within an intranasal liposomal formulation combining toll-like receptor 4 (TLR4) and Toll-like receptor 7/8 ligands. This mucosal vaccination strategy provided broad, durable protection in mice for at least three months against both SARS-CoV-2 (COVID-19) and Staphylococcus aureus. The use of OVA as the model antigen allowed investigators to validate the immunogenicity and longevity of the mucosal immune response, demonstrating that TLR co-stimulation could drive robust protection against diverse respiratory threats, with implications for next-generation intranasal vaccines.

Allergic Disease Modeling

Ovalbumin-induced sensitization models remain the gold standard for studying allergic airway disease. A 2026 study in International Immunopharmacology (PMID: 41846060) used OVA-induced murine allergic asthma to investigate whether isorhapontigenin could attenuate airway inflammation, oxidative stress, and airway hyperresponsiveness (AHR). Results suggested that isorhapontigenin reduced proinflammatory cytokine levels and oxidative stress markers in bronchoalveolar lavage fluid, providing mechanistic evidence of its therapeutic potential. In a separate study (European Journal of Pharmacology, PMID: 42103052), OVA was used to induce Henoch-Schönlein purpura (HSP) in a rat model to evaluate the protective effects of rutin. rutin attenuated inflammation and protected intestinal barrier function, with OVA sensitization driving the IgA immune complex deposition central to HSP pathogenesis. A further study (Journal of Controlled Release, PMID: 41819426) used an OVA-induced murine allergic rhinitis model to evaluate a dual-action nasal spray formulating mussel protein (Mefp) and xylitol; Mefp treatment significantly alleviated allergic symptoms, reduced eosinophil infiltration, decreased OVA-specific IgE levels, and enhanced antioxidant enzyme activities in the nasal epithelium.

Drug and Vaccine Delivery Formulation

Several recent publications exploited ovalbumin's amphiphilic and emulsifying properties for advanced drug and vaccine delivery. A 2026 Food Chemistry study (PMID: 41833136) prepared OVA/gum arabic complexes via direct mixing and demonstrated their efficacy as emulsifiers stabilizing the external aqueous phase of water-in-oil-in-water (W/O/W) double emulsions, enabling effective delivery of vitamin B12. Fourth-order derivative fluorescence spectroscopy was applied to characterize interfacial protein behavior in these complex systems. A separate International Journal of Pharmaceutics study (PMID: 41903784) developed optimized dual delivery systems incorporating OVA-loaded liposomes within W/O/W multiple emulsion systems to enhance vaccine antigen delivery, assessing cellular uptake and immune activation in vitro.

In food preservation research (Food Chemistry, PMID: 41921443), ovalbumin was used as a structural matrix in the fabrication of tannic acid–Fe(III) metal polyphenol network-coated gallic acid-loaded OVA/chitosan nanoparticles embedded within gelatin hydrogels. These systems exhibited adhesion and sustained antibacterial properties, extending the shelf life of prefabricated meat.

Finally, a Biopolymers study (PMID: 41889002) incorporated ovalbumin as a phosphorylated globular protein within a biomimetic dual-protein semi-interpenetrating polymer network (semi-IPN) platform alongside collagen, embedded in a bioactive polyurethane-crosslinked matrix. This system was evaluated for wound healing, immunomodulation, and mineralization, with growth factors TGF-β1 and VEGF implicated in mediating the biological response.

Key Publications

• Jun A sustained-release antibacterial gelatin hydrogel based on metal-phenolic networks for long-term preservation of prefabricated meat. (Food chemistry, 2026, PMID 41921443): "In this study, tannic acid -FeIII metal polyphenol network-coated gallic acid -loaded ovalbumin/chitosan nanoparticles with adhesion and sustainable antibacterial properties were prepared and embedded into the gelatin hydrogel to elongate the shelf life of prefabricated meat."
• Jun Construction, characterization, and evaluation of nanosized curdlan sulfate/quaternary ammonium chitosan/CpG ODN polyelectrolyte complex as an adjuvant for tumor vaccine. (International journal of biological macromolecules, 2026, PMID 42119872): "Moreover, their adjuvant properties and antitumor effects were assessed using ovalbumin (OVA) as a model antigen."
• May Therapeutic effect of rutin on Henoch-Schönlein purpura by attenuating inflammation and protection of the intestinal barrier function in rats. (European journal of pharmacology, 2026, PMID 42103052): "This study aimed to investigate the protective effects of rutin in a rat model of HSP induced by ovalbumin."
• May Mucosal vaccination in mice provides protection from diverse respiratory threats. (Science (New York, N.Y.), 2026, PMID 41712698): "We describe an intranasal liposomal formulation combining toll-like receptor 4 and 7/8 ligands with a model antigen, ovalbumin, which provided broad, durable protection in mice for at least 3 months against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Staphylococcus aureus."
• May Isorhapontigenin attenuates allergic asthma by reducing airway inflammation and oxidative stress. (International immunopharmacology, 2026, PMID 41846060): "we examined whether isorhapontigenin can ameliorate airway inflammation, oxidative stress, and airway hyperresponsiveness (AHR) in an ovalbumin (OVA)-induced mouse model of allergic asthma."
• May Interfacial behavior and stability of ovalbumin/gum arabic complex stabilized W/O/W emulsion: fourth derivative fluorescence method. (Food chemistry, 2026, PMID 41833136): "In this study, ovalbumin (OVA)/gum arabic (GA) complexes were prepared via direct mixing and used as emulsifiers to stabilize the external aqueous phase of W/O/W double emulsions, creating an effective vitamin B12 (VB12) delivery system."
• May Dual-action nasal spray with mussel protein and xylitol restores epithelial barrier and attenuates type 2 inflammation in allergic rhinitis. (Journal of controlled release : official journal of the Controlled Release Society, 2026, PMID 41819426): "In an ovalbumin-induced murine AR model, Mefp treatment markedly alleviated allergic symptoms, reduced eosinophil infiltration, decreased OVA-specific IgE levels, and enhanced antioxidant enzyme activities."
• May Development and in vitro cellular evaluation of optimised multiple emulsion and liposomes-in-emulsion adjuvant systems for vaccine delivery. (International journal of pharmaceutics, 2026, PMID 41903784): "This study aimed to develop and optimize a dual delivery system incorporating ovalbumin (OVA) liposomes in a multiple W/O/W emulsion system for vaccine delivery."
• May Targeted enhancement of antigen cross-presentation capability of M2-like tumor-associated macrophages to boost glioblastoma immunotherapy. (Biomaterials, 2026, PMID 41370882): "The abundant M2-like TAMs in GBM can directly cross-present the OVA antigen carried by NPs-RuIn-M to effectively promote the activation and proliferation of CD8+ T cells, thereby inhibiting the growth of GBM."
• May Biomimetic Double-Protein Semi-IPN Hydrogels: Synergistic Protein-Polysaccharide Biomatrices for Healing, Immunomodulation, and Mineralization. (Biopolymers, 2026, PMID 41889002): "This study introduces a biomimetic dual-protein semi-interpenetrating polymer network (semi-IPN) platform integrating collagen (C) and the phosphorylated globular protein ovalbumin within a bioactive polyurethane (PU) cross-linked matrix."